company hearing

Acousia Therapeutics, a hearing loss company, will present data for ACOU085 during ARO 2022 MidWinter meeting February 59

Tübingen, Germany, January 26, 2022 – Acousia Therapeutics GmbH – along with its partners from the Translational Hearing Research Group at the Tübingen Hearing Research Center (Department of Otolaryngology, Head and Neck Surgery, University of Tübingen) and Synovo GmbH (Tübingen) – will be presenting data on the the company’s clinical stage lead candidate ACOU085 at…


Tubingen, Germany. January 2022 Acousia Therapeutics GmbH will present data on the clinical stage lead candidate for ACOU at The 45th Annual MidWinter Meeting of Association for Research in Otolaryngology. It will take place virtually on February 59. 2022.

ACOU 085, a proprietary small-molecule, otoprotective candidate drug, is available. It was granted a CTA in December 2021, to initiate the first-in-human Phase1b clinical trial by German BfArM. At the 2022 ARO MidWinter Meeting, ACOU will present preclinical pharmacology and pharmacokinetic data.

The Small-Molecule KCNQ4 Anogist Protects against Outer Hair Cell Loss in a SAMP8 Mouse Model Age-Related to Hearing Loss (Peixoto Pinheiro and al. )

This proof-of-concept study uses the senescence-accelerated mouse prone 8 (SAMP8) model to demonstrate the ability of repeated ACOU085 administrations to significantly reduce age-related ABR threshold shifts. This was supported by a histological demonstration of reduced OH

Read More

Leave a Reply

Your email address will not be published.